Candel Therapeutics Ownership | Who Owns Candel Therapeutics?

Candel Therapeutics Ownership Summary

Candel Therapeutics is owned by 72.70% institutional investors, 16.76% insiders, and 10.54% retail investors. Fmr is the largest institutional shareholder, holding 12.26% of CADL shares. Fidelity Select Biotechnology is the top mutual fund, with 10.10% of its assets in Candel Therapeutics shares.

CADL Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Candel Therapeutics	72.70%	16.76%	10.54%
Sector	Healthcare Stocks	488.30%	11.08%	-399.38%
Industry	Biotech Stocks	307.10%	11.11%	-218.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Fmr	3.92M	12.26%	$34.06M
Blackrock funding, inc. /de	2.30M	7.27%	$11.65M
Northpond ventures	1.94M	6.63%	$12.00M
Portolan capital management	1.62M	5.12%	$8.21M
Vanguard group	1.34M	4.18%	$11.62M
Blackrock	823.07K	2.82%	$5.10M
State street	560.97K	1.75%	$4.87M
Geode capital management	455.42K	1.42%	$3.95M
Halter ferguson financial	698.00K	1.36%	$3.56M
Sands capital ventures	405.84K	1.28%	$2.05M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Northpond ventures	1.94M	21.71%	$12.00M
Halter ferguson financial	698.00K	0.81%	$3.56M
Portolan capital management	1.62M	0.51%	$8.21M
Sands capital ventures	405.84K	0.40%	$2.05M
Birchview capital, lp	60.00K	0.30%	$303.60K
Tanager wealth management llp	198.18K	0.11%	$1.01M
Entrypoint capital	17.24K	0.04%	$87.25K
Taylor financial group	10.00K	0.03%	$50.60K
Baker bros. advisors lp	355.11K	0.02%	$1.80M
Xtx topco	74.63K	0.02%	$377.62K

Top Buyers

Holder	Shares	% Assets	Change
Fmr	3.92M	0.00%	3.92M
Blackrock	823.07K	0.00%	775.49K
Portolan capital management	1.62M	0.51%	740.54K
Blackrock funding, inc. /de	2.30M	0.00%	538.08K
Vanguard group	1.34M	0.00%	392.88K

Top Sellers

Holder	Shares	% Assets	Change
Baker bros. advisors lp	355.11K	0.02%	-2.08M
Braidwell lp	-	-	-1.60M
Franklin resources	-	-	-211.01K
Halter ferguson financial	698.00K	0.81%	-78.51K
Bridgeway capital management	-	-	-77.19K

New Positions

Holder	Shares	% Assets	Change	Value
Xtx topco	74.63K	0.02%	74.63K	$377.62K
Alps advisors	27.05K	0.00%	27.05K	$136.85K
Cubist systematic strategies	26.12K	0.00%	26.12K	$161.95K
Virtu financial	22.64K	0.01%	22.64K	$140.00K
Morgan stanley	19.46K	-	19.46K	$120.64K

Sold Out

Holder	Change
Qube research	-1.00
National bank of canada /fi/	-3.00
True wealth design	-8.00
Eversource wealth advisors	-38.00
Signaturefd	-39.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	83	-5.68%	23,028,788	8.68%	72	4.13%	56	-11.11%	16	33.33%
Mar 31, 2025	88	12.82%	21,199,863	18.25%	41	1.34%	63	16.67%	12	50.00%
Dec 31, 2024	22	-60.71%	2,942,258	-56.04%	9	2.10%	15	-51.61%	4	-60.00%
Sep 30, 2024	56	14.29%	6,693,231	12.27%	20	5.01%	31	-26.19%	10	150.00%
Jun 30, 2024	49	157.89%	5,961,761	57.71%	20	11.96%	42	366.67%	4	-20.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Fidelity Select Biotechnology	5.54M	10.10%	-
Fidelity Growth Compy Commingled Pl S	1.24M	2.25%	1.70K
Vanguard Total Stock Mkt Idx Inv	1.08M	2.16%	217.04K
iShares Russell 2000 ETF	940.31K	1.71%	-
Fidelity Growth Company Fund	907.97K	1.65%	-5.43K
Strategic Advisers U.S. Total Stock	878.66K	1.60%	257.57K
BANOR SICAV Rosemary S EUR Acc	440.00K	0.88%	80.00K
Vanguard Institutional Extnd Mkt Idx Tr	389.28K	0.78%	-177.38K
Fidelity Small Cap Index	394.96K	0.72%	104.90K
iShares Russell 2000 Growth ETF	311.51K	0.57%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jul 28, 2025	Nichols William Garrett	Chief Medical Officer	Sell	$6.54K
Jun 30, 2025	Nichols William Garrett	Chief Medical Officer	Sell	$3.94K
Mar 18, 2025	Nichols William Garrett	Chief Medical Officer	Sell	$397.00K
Mar 18, 2025	Barone Francesca	Chief Scientific Officer	Sell	$281.67K
Mar 18, 2025	Tak Paul Peter	Chief Executive Officer	Sell	$226.02K

Insider Transactions Trends

Date	Buy	Sell
2025 Q3	-	1
2025 Q2	-	1
2025 Q1	-	16
2024 Q4	2	10
2024 Q3	-	10

CADL Ownership FAQ

Who Owns Candel Therapeutics?

Candel Therapeutics shareholders are primarily institutional investors at 72.70%, followed by 16.76% insiders and 10.54% retail investors. The average institutional ownership in Candel Therapeutics's industry, Biotech Stocks , is 307.10%, which Candel Therapeutics falls below.

Who owns the most shares of Candel Therapeutics?

Candel Therapeutics’s largest shareholders are Fmr (3.92M shares, 12.26%), Blackrock funding, inc. /de (2.3M shares, 7.27%), and Northpond ventures (1.94M shares, 6.63%). Together, they hold 26.15% of Candel Therapeutics’s total shares outstanding.

Does Blackrock own Candel Therapeutics?

Yes, BlackRock owns 2.82% of Candel Therapeutics, totaling 823.07K shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 5.1M$. In the last quarter, BlackRock increased its holdings by 775.49K shares, a 1629.87% change.

Who is Candel Therapeutics’s biggest shareholder by percentage of total assets invested?

Northpond ventures is Candel Therapeutics’s biggest shareholder by percentage of total assets invested, with 21.71% of its assets in 1.94M Candel Therapeutics shares, valued at 12M$.

Who is the top mutual fund holder of Candel Therapeutics shares?

Fidelity Select Biotechnology is the top mutual fund holder of Candel Therapeutics shares, with 10.10% of its total shares outstanding invested in 5.54M Candel Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools